Healthy Clinical Trial
— vFASTOfficial title:
Quantification of Agreement and Variability Characteristics of a Newly Developed Visual Field Algorithm With the Reference Standard: an Observational Study
| NCT number | NCT02727569 |
| Other study ID # | GART1046 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | June 15, 2017 |
| Est. completion date | June 29, 2018 |
| Verified date | July 2020 |
| Source | Moorfields Eye Hospital NHS Foundation Trust |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This study aims to compare two types of visual field test; retinal sensitivity values
obtained with the reference standard Swedish Interactive Thresholding Algorithm (SITA) of the
standard visual field test and with a newly developed test algorithm. The new test is a
visual field test presented on a flat-panel monitor and has two modes: differential light
sensitivity (DLS; equivalent to the standard visual field test) and the Moorfields Motion
Displacement Test (MMDT). DLS sensitivity and DLS measurement variability will be determined
and compared between the SITA algorithm of the standard visual field test and the new visual
field test on the flat-panel monitor. The measurement variability of the MMDT will be
quantified.
The long-term goal is to reduce test variability below that observed in SITA by 20%, whilst
producing comparable measurements (contrast threshold values) for comparable test duration.
| Status | Completed |
| Enrollment | 110 |
| Est. completion date | June 29, 2018 |
| Est. primary completion date | June 29, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 100 Years |
| Eligibility |
Inclusion Criteria: - Best corrected visual acuity of 6/12 or better in the test eye - No ocular morbidity other than glaucoma; early lens opacity and prior cataract surgery are acceptable Healthy eyes - Central 30° visual field within normal limits on the 24-2 test (MD within 95 % CI and glaucoma hemifield test within normal limits). Glaucoma eyes - More than two reliable visual fields with reproducible defects - IOP < 30 mmHg Exclusion Criteria: - Any systemic disease which is likely to affect visual performance in a short period of time - Inability to steadily fixate on the test (e.g. individuals who have nystagmus or macular degeneration) - Eyes with unreliable visual fields (defined as false positive responses >15%) |
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | Moorfields Eye Hospital | London |
| Lead Sponsor | Collaborator |
|---|---|
| Moorfields Eye Hospital NHS Foundation Trust |
United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To quantify the threshold difference in the test-retest variability of DLS obtained with the new algorithm and the SITA algorithm. To quantify the threshold test-retest variability of the MMDT with the new algorithm. | Through study completion, an average of 1 year. | ||
| Secondary | To quantify the difference in DLS thresholds measured with the new and SITA algorithms across all retinal locations and for a range of visual field sensitivities. | Through study completion, an average of 1 year. | ||
| Secondary | To determine whether any differences in thresholds obtained on the two algorithms vary with retinal eccentricity and stimulus energy. Mean difference for each location will be reported in decibels. | Through study completion, an average of 1 year. | ||
| Secondary | To determine whether any differences in test-retest variability obtained on the two algorithms vary with retinal eccentricity and stimulus energy. Mean difference between test-retest for each location will be reported in decibels. | Through study completion, an average of 1 year. | ||
| Secondary | Participants preference for a more reliable visual fields test or for having a shorter test (questionnaire). | Through study completion, an average of 1 year. | ||
| Secondary | Participants preference of test strategy, MMDT or DLS (questionnaire). | Through study completion, an average of 1 year. | ||
| Secondary | Participants preference of test algorithm, newly developed algorithms or the SITA algorithm (questionnaire). | Through study completion, an average of 1 year. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |